KLONOPIN RAPIDLY DISINTEGRATING
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLONOPIN Rapidly Disintegrating is an orally disintegrating tablet formulation of clonazepam, a benzodiazepine small molecule. The product treats anxiety disorders and seizure disorders by enhancing GABA receptor activity in the central nervous system. This formulation addresses patient convenience through rapid dissolution without water.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition planning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLONOPIN Rapidly Disintegrating offers exposure to defensive brand management and LOE preparation strategies in a mature market. Career trajectory emphasizes market access, generic collaboration, and lifecycle extension rather than growth-phase innovation.
Brand ManagerMedical Science Liaison
Worked on KLONOPIN RAPIDLY DISINTEGRATING at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.